MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain

Not Applicable

Withdrawn

Conditions: Hematopoietic/Lymphoid Cancer
Pain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: placebo
Drug: olanzapine

First Posted Date: 2008-08-18

Last Posted Date: 2012-03-09

Lead Sponsor: Mayo Clinic

Registration Number: NCT00737191

Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome

Phase 1

Terminated

Conditions: Empty Nose Syndrome
Atrophic Rhinitis

Interventions: Drug: Botulinum Toxin Type A

First Posted Date: 2008-08-12

Last Posted Date: 2016-04-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 9

Registration Number: NCT00732680

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Prospective Trial of Elective Extubation in Brain Injured Patients.

Phase 1

Completed

Conditions: Brain Injury

Interventions: Procedure: continued intubation
Procedure: extubation

First Posted Date: 2008-08-07

Last Posted Date: 2015-04-28

Lead Sponsor: Mayo Clinic

Target Recruit Count: 16

Registration Number: NCT00729261

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Gastroesophageal Reflux Disease
GERD
Eosinophilic Esophagitis
EE

Interventions: Drug: Esomeprazole
Drug: Budesonide

First Posted Date: 2008-08-05

Last Posted Date: 2016-01-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 51

Registration Number: NCT00728481

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

Phase 2

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Bortezomib

First Posted Date: 2008-07-28

Last Posted Date: 2016-05-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 18

Registration Number: NCT00722722

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence

Phase 2

Completed

Conditions: Tobacco Dependence

Interventions: Drug: S-Adenosyl-L-Methionine
Other: placebo

First Posted Date: 2008-07-25

Last Posted Date: 2011-09-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 150

Registration Number: NCT00722124

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Franciscan Skemp HealthCare, La Crosse, Wisconsin, United States

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Procedure: assessment of therapy complications
Drug: anastrozole
Drug: exemestane
Drug: letrozole

First Posted Date: 2008-07-22

Last Posted Date: 2024-01-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 109

Registration Number: NCT00719966

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: brachytherapy
Radiation: hypofractionated radiation therapy
Radiation: image-guided radiation therapy
Radiation: intensity-modulated radiation therapy

First Posted Date: 2008-07-14

Last Posted Date: 2019-08-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 5

Registration Number: NCT00714753

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty

Not Applicable

Terminated

Conditions: Recovery Time
Bruising

Interventions: Procedure: Septorhinoplasty
Drug: Fibrinogen
Procedure: Taping after septorhinoplasty.
Other: Saline
Procedure: Cast applied to the nose after nasal surgery

First Posted Date: 2008-07-11

Last Posted Date: 2016-04-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 25

Registration Number: NCT00713596

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma
Refractory Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Nodal Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Waldenstrom Macroglobulinemia

Interventions: Drug: Bortezomib
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Dexamethasone
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2008-07-09

Last Posted Date: 2019-04-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 21

Registration Number: NCT00711828

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy